Published by Global Banking & Finance Review®
Posted on March 6, 2025
1 min readLast updated: January 25, 2026
Add as preferred source on GoogleMerck KGaA expects up to 8% growth in forex-adjusted earnings for 2025, driven by semiconductor chemicals and biotech lab equipment demand.
FRANKFURT (Reuters) - Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor chemicals and for lab equipment in biotech drug production.
The German group said in a statement that 2025 earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for special items, would likely reach between 6.1 billion euros ($6.6 billion) and 6.6 billion euros.
That would be up from 6.07 billion euros reported for 2024, which was broadly in line with the average analyst estimate.
($1 = 0.9258 euros)
(Reporting by Ludwig Burger, Editing by Miranda Murray)
Merck KGaA forecasts currency-adjusted operating earnings growth of up to 8% for this year.
The growth is supported by demand for semiconductor chemicals and lab equipment in biotech drug production.
The company expects its EBITDA, adjusted for special items, to reach between 6.1 billion euros and 6.6 billion euros in 2025.
The forecast for 2025 shows an increase from the 6.07 billion euros reported for 2024, which was in line with average analyst estimates.
The article states that $1 is equivalent to 0.9258 euros.
Explore more articles in the Headlines category
